MedPath

BackToBasic: The effect of Infliximab in patients with chronic low back pain and vertebral oedema on MRI scan.A randomized, double blind, placebo-controlled, multicenter trial

Phase 1
Conditions
on-specific chronic low back pain of more than 6 months duration. We will only investigate those who have vertebral end-plate chanages(Modic changes) on MRI.
MedDRA version: 20.0Level: LLTClassification code 10008837Term: Chronic back painSystem Organ Class: 100000004859
Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]
Registration Number
EUCTR2017-004861-29-NO
Lead Sponsor
FOU, Nevroklinikken, Oslo University Hospital -Ullevål
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Recruiting
Sex
All
Target Recruitment
126
Inclusion Criteria

-Age between 18 and 65 years
-Low back pain of > 6 months duration with a Numerical Rating Scale (NRS) pain intensity score of 5
-Modic Changes type I in the lumbar vertebral body

Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 126
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

-Any contraindication or increased risk of side-effects from Infliximab (such as ongoing infection, recent live vaccination or planned live vaccination, immunocompromised, ongoing glucocorticoid treatment or allergy against any products of the medication)
- Current pregnancy or lactation
- For women of childbearing potential; inadequate birth control, pregnancy, and/or breastfeeding.
- Not able to understand written and spoken Norwegian
- Not able to complete treatment or follow-ups in the study (i.e. contraindications for MRI, severe psychiatric disease, drug abuse or plans of moving)

Study & Design

Study Type
Interventional clinical trial of medicinal product
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath